Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study ☆
Titel:
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study ☆
Auteur:
Gratzke, C. Özgüroğlu, M. Peer, A. Sendur, M.A.N. Retz, M. Goh, J.C. Loidl, W. Jayram, G. Byun, S.-S. Kwak, C. Kwiatkowski, M. Manneh Kopp, R. Limón, J.C.V. Penagos, J.F.E. De Giorgi, U. da Trindade, K.M. Niu, C. Liu, Y. Poehlein, C.H. Piulats, J.M.
Verschenen in:
Annals of oncology
Paginering:
Jaargang 36 () nr. 8 pagina's 964-975
Jaar:
2025
Inhoud:
Uitgever:
Merck & Co., Inc., Rahway, NJ, USA and its affiliates, The Author(s)